Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Not Recruiting

Trial ID: NCT02026063


The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Official Title

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Stanford Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine


Inclusion Criteria:

* Ongoing participation in a Phase 2 \[LX1606.1-202-CS (NCT00853047), LX1606.1-203-CS (NCT01104415)\] or Phase 3 \[LX1606.1-301-CS (NCT01677910), LX1606.1-303-CS (NCT02063659)\] study
* Patients of childbearing potential must agree to use an adequate method of contraception (defined as having a failure rate of \<1% per year) during the study and for 12 weeks after the Follow-up visit.
* Ability and willingness to provide written informed consent

Exclusion Criteria:

* Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS, LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study
* Positive pregnancy test
* Presence of any clinically significant findings at entry for medical history, laboratory values, or physical examination


drug: Telotristat etiprate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

New Trial Alerts